ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Integrating UPLC-HR-MS, network pharmacology and experimental validation to reveal the potential mechanism of Fuzheng Bixie granules in treating acute lung injury.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Acute lung injury (ALI) is a severe pulmonary complication. Fuzheng Bixie Granules (FZBXG) is a traditional Chinese medicine formula with significant antipyretic, anti-inflammatory, analgesic, and microcirculation-improving effects. In clinical practice, it is used to treat patients with pneumonia and lung injury caused by viral infections, demonstrating favorable efficacy, and its clinical value has been preliminarily validated. However, a deeper understanding of its anti-lung injury mechanisms and the identification of its core active components will contribute to a more comprehensive insight into the potential applications of FZBXG in the treatment of ALI. In this study, the bioactive components of FZBXG was firstly analyzed by UPLC-HR-MS technology. Network pharmacology was utilized to identify related targets and potential pathways of FZBXG in the treatment of ALI. Additionally, LPS-stimulated Raw264.7 inflammatory cell models and ALI mouse models were established for validation. Eventually, a total of 189 chemical components were identified, mainly flavonoids, terpenes and glycosides. Network pharmacology analysis revealed that FZBXG is involved in the treatment of ALI through the IL-17 signaling pathway, NF-κB signaling pathway, and TNF signaling pathway. Animal experiments showed that FZBXG treatment significantly alleviated lung pathology, attenuate inflammatory responses in mice with ALI. FZBXG reduced the expression of phosphorylated AKT, p38 MAPK, and NF-κB while upregulated Nrf2/HO-1 signaling. Through the analysis of the active components of FZBXG and its mechanisms against acute lung injury, a theoretical basis is provided for the clinical promotion of FZBXG.
Indexed as
Identifiers
41128900What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.